


SPRY2
Anti-SPRY2 Recombinant Antibody Products
-
- Derivation: Phage display library screening
- Species Reactivity: Rat, Human
- Type: IgG
- Application: WB, IHC-P, ICC/IF, IP
Can't find the products you're looking for? Try to filter in the left sidebar.Filter By Tag
Our customer service representatives are available 24 hours a day, from Monday to Sunday. Contact Us
For Research Use Only. Not For Clinical Use.
Disease related genes, Plasma proteins
Membrane
Low cell type specificity
Immune cell enhanced (NK-cell)
Cell line enhanced (AN3-CA, SK-MEL-30, WM-115)
Forms heterodimers with SPRY1 (By similarity). Forms a tripartite complex containing GAB1, METTL13 and SPRY2 (PubMed:29408807). Within the complex interacts with METTL13 (PubMed:29408807). Interacts with RAF1 (PubMed:12717443). Interacts (via C-terminus) with TESK1 (via C-terminus); the interaction disrupts SPRY2 interaction with GRB2, potentially via disruption of SPRY2 serine dephosphorylation (PubMed:17974561). Interacts with PPP2R1A/PP2A-A and PPP2CA/PP2A-C; the interaction with PPP2CA/PP2A-C is inhibited by interaction with TESK1, possibly by vesicular sequestration of SPRY2 (PubMed:17974561). Inhibition of the interaction with the serine/threonine-protein phosphatase 2A (PP2A) holoenzyme results in loss of PP2A-mediated dephosphorylation, resulting in the loss of SPRY2 interaction with GRB2 (PubMed:17974561). Interacts with GRB2 (PubMed:17974561). Interacts with CBL/C-CBL; the interaction inhibits CBL-mediated ubiquitination of EGFR (PubMed:17974561). Interacts (via C-terminus) with CAV1 (via C-terminus) (PubMed:16877379).
Developmental protein